Mesenchymal Cell News 10.13 April 3, 2018 | |
| |
TOP STORYScientists explored how the proteome and metabolome of MSCs changes when cells were exposed to 48 hours of 1% oxygen, interferon gamma (IFN-γ), or both cues together. IFN-γ promoted expression of anti-pathogenic proteins and induced MSCs to limit inflammation and fibrosis while promoting their own survival. Hypoxia instead led to cell adaptation to low oxygen, including upregulation of proteins involved in anaerobic metabolism, autophagy, angiogenesis, and cell migration. [Biomaterials] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)IN VITROEnhanced Osteogenic Differentiation of Stem Cells on Phase-Engineered Graphene Oxide Investigators induced a phase transformation in graphene oxide (GO) and demonstrated its benefits for enhanced stem cell culture and differentiation, while conserving the oxygen content. The transformation resulted in clustering of oxygen atoms on the GO surface, which greatly improved its ability toward substance adherence and resulted in enhanced differentiation of human MSCs towards the osteogenic lineage. [ACS Appl Mater Interfaces] Abstract Scientists describe the extensive and systematic exploration of three architectural variations of star-shaped poly(L-Lysine) polypeptide (star-PLL) with varying number and length of poly(L-Lysine) arms as potential non-viral gene delivery vectors for MSCs. [Mol Pharm] Abstract In vitro analyses revealed that interleukin‐1 receptor antagonist (IL‐1Ra) protein present in conditioned medium from MSC/IL‐1Ra cells blocks osteoarthritis onset in cytokine‐treated equine chondrocytes and co‐cultivation of MSC/IL‐1Ra cells with osteoarthritic spheroids alleviates the severity of the osteoarthritic changes. [J Gene Med] Abstract Osteogenic differentiation was improved by co-culturing osteoblasts (OBs) and adipose-derived mesenchymal stem cells (Ad-MSCs) when compared to the individual mono-cultures. An OB to Ad-MSC ratio of 3:1 had best effects on total protein content, alkaline phosphatase activity, and matrix mineralization. [Int J Mol Sci] Full Article Treatment of Arsenite Intoxication-Induced Peripheral Vasculopathy with Mesenchymal Stem Cells The authors attempted to find that treatment with MSCs may be effective for arsenite (As)-induced vasculopathy. They conducted an in vitro study with a co-culture system containing human MSCs and human umbilical vein endothelial cells and treated individual and co-cultured cells with various concentrations of arsenite. [Int J Mol Sci] Full Article Researchers compared human fibroblasts, bone marrow-derived MSCs, and adipose-derived mesenchymal stem cells as a supporting source for cell sheets. [Islets] Abstract IN VIVOResearchers developed a unique, truly active tumor targeting strategy that relies on engineering MSCs with drug-loaded nanoparticles. Their studies using the A549 orthotopic lung tumor model showed that nano-engineered MSCs carrying the anticancer drug paclitaxel home to tumors and create cellular drug depots that release the drug payload over several days. [Mol Cancer Ther] Abstract Researchers observed that β2-microglobulin (B2M) is highly expressed in MSCs but scarcely in esophageal squamous cell carcinoma (ESCC) cells. They investigated the in vitro effect of MSCs-derived B2M on the epithelial-mesenchymal transition of ESCC cells, and discovered its subsequent enhancing effects on cell mobility and tumor-initiation. [Sci Rep] Full Article | |
| |
REVIEWSMSC Cross‐Talk with Cancer Cells Provides Therapeutic Potential Various direct and indirect cellular interactions between multi‐functional MSC and cancer cells contribute to increasing plasticity within the tumor tissue and its microenvironment. The authors focus on vesicle‐mediated indirect communication and on cancer cell fusion with direct contact between MSC and cancer cells. [Stem Cells] Abstract Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field. | |
| |
INDUSTRY NEWSFDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus™ MSC Product, CYP-001 Cynata Therapeutics Limited announced that the FDA has granted Cynata Orphan Drug Designation for CYP-001 for the treatment of acute graft versus host disease. CYP-001 is the lead MSC product manufactured using Cynata’s proprietary Cymerus platform manufacturing technology. [GlobeNewswire (Cynata Therapeutics Limited)] Press Release Mesoblast Phase III Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment Mesoblast Limited announced that enrollment has completed in the Phase III trial evaluating a single intra-discal injection of its proprietary allogeneic mesenchymal precursor cell product candidate MPC-06-ID in patients with chronic low back pain due to degenerative disc disease. [Mesoblast Limited] Download Press Release | |
| |
POLICY NEWSCancer Researchers Push to Relax Rules for Clinical Trials US government examines whether criteria for participating in drug studies unnecessarily exclude some people. [Nature News] Editorial EU Copyright Reforms Draw Fire from Scientists An influential committee of the European Parliament is due to vote on changes to copyright regulations in the European Union (EU), but the latest drafts of the rules have triggered a wave of criticism from open-science advocates. They say that the proposals will stifle research and scholarly communication. [Nature News] Editorial Cancer Researcher at the Ohio State University Resigns following Multiple Misconduct Findings A cancer researcher has resigned from The Ohio State University in Columbus after the institution determined he had committed misconduct in eight papers. His work in designing anticancer compounds had led to millions of dollars in funding and multiple patents, as well as two compounds in clinical trials. [ScienceInsider] Editorial French Universities Cancel Subscriptions to Springer Journals French research organizations and universities have canceled their subscriptions to Springer journals, due to an impasse in fee negotiations between the publisher and Couperin.org, a national consortium representing more than 250 academic institutions in France. [The Scientist] Editorial
| |
EVENTSNEW 2nd International Symposium for Molecular Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Fellow – Musculoskeletal Tissue Regeneration (University of South Dakota) Postdoctoral Fellow – Bone Biology (Cornell University) Postdoctoral Positions – Bioengineering (George Washington University) Postdoctoral Fellowship – Skeletal Stem Cell Biology (Johns Hopkins University) Faculty Position – Stem Cell Biology and Regenerative Medicine (University of Illinois) Postodoctoral Fellowship – Cell and Molecular Biology (Canadian Nuclear Laboratories) Postdoctoral Researcher – Cell Biology (University of Pennsylvania) Postdoctoral Fellow – Bone Biology and Osteoimmunology (Weill Cornell Medicine) Full Professor Position – Cell and Developmental Biology (Max F. Perutz Laboratories) Lectureship – Stem Cell Biology (University of Edinburgh) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|